GoodRx (GDRX) Projected to Release Earnings on Tuesday

GoodRx (NASDAQ:GDRX) will likely be issuing its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect GoodRx to announce earnings of $0.0777 per share and revenue of $202.07 million for the quarter. Investors may review the information on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 8:00 AM ET.

GoodRx (NASDAQ:GDRX) last posted its quarterly earnings results on Wednesday, August 5th. The company reported $0.08 earnings per share for the quarter, meeting the consensus estimate of $0.08. The firm had revenue of $200.41 million for the quarter, compared to analyst estimates of $193.23 million. GoodRx had a return on equity of 7.22% and a net margin of 2.07%. GoodRx’s quarterly revenue was down 1.3% on a year-over-year basis. During the same period in the previous year, the firm earned $0.09 earnings per share. On average, analysts expect GoodRx to post $0.16 EPS for the current fiscal year and $0.20 EPS for the next fiscal year.

GoodRx Stock Up 0.6%

Shares of GoodRx stock opened at $3.56 on Tuesday. The stock has a 50-day moving average price of $3.44 and a 200 day moving average price of $2.81. The company has a market cap of $1.22 billion, a P/E ratio of 89.02, a P/E/G ratio of 1.76 and a beta of 1.69. The company has a current ratio of 1.38, a quick ratio of 1.38 and a debt-to-equity ratio of 0.74. GoodRx has a 1 year low of $1.77 and a 1 year high of $3.99.

Wall Street Analyst Weigh In

Several equities analysts have weighed in on GDRX shares. Wall Street Zen raised GoodRx from a “hold” rating to a “buy” rating in a research note on Saturday, August 15th. Barclays upped their target price on GoodRx from $3.00 to $4.00 and gave the company an “underweight” rating in a report on Thursday, August 20th. Wells Fargo & Company increased their price target on shares of GoodRx from $3.50 to $5.00 and gave the stock an “overweight” rating in a research report on Friday, August 7th. Weiss Ratings raised shares of GoodRx from a “sell (d)” rating to a “sell (d+)” rating in a research report on Friday, August 7th. Finally, Leerink Partners set a $5.00 price target on shares of GoodRx in a report on Thursday, August 6th. Four research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and three have issued a Sell rating to the company. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average price target of $4.23.

Insider Activity

In related news, major shareholder Francisco Partners Iv, L.P. sold 1,296,177 shares of GoodRx stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $3.50, for a total transaction of $4,536,619.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders sold 2,760,995 shares of company stock worth $9,673,207 in the last ninety days. 5.87% of the stock is currently owned by company insiders.

GoodRx Company Profile

GoodRx Holdings, Inc operates a digital healthcare platform that helps consumers find and access lower prices for prescription medications. Through its website and mobile applications, GoodRx allows users to compare prices at participating pharmacies, obtain prescription discount coupons and identify potential savings on commonly prescribed drugs. The company’s services are generally available at pharmacies across the United States.

GoodRx also offers GoodRx Gold, a membership program that provides additional discounts on eligible prescriptions, as well as healthcare-related content and tools designed to help consumers understand medications and treatment options.